Eli Lilly presented new exploratory biomarker data from its TOGETHER-PSO Phase 3b trial, suggesting an immunometabolic relationship between psoriasis and obesity. The data indicates that combining Taltz and Zepbound leads to broader positive changes in psoriasis and metabolic biomarkers compared to Taltz alone, supporting a more comprehensive treatment approach for patients with both conditions.
Eli Lilly presented new exploratory biomarker data from its TOGETHER-PSO Phase 3b clinical trial. The findings suggest that combining Taltz (for psoriasis) and Zepbound (for obesity) leads to more significant and broader positive changes in both psoriasis-associated and metabolic biomarkers compared to Taltz alone. This is important because a large percentage of psoriasis patients also suffer from obesity, and these results support a more integrated treatment approach, potentially expanding the market and efficacy perception for both drugs. For traders, this reinforces the strong pipeline and market position of Eli Lilly, particularly in the immunology and metabolic disease spaces, offering a long-term positive outlook for the stock, though the immediate market impact might be moderate as this is exploratory data following previously reported clinical outcomes.